Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2027 ended September 30, 2026 and Provides Conference Call Information
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Elite Pharmaceuticals (ELTP) reported second-quarter fiscal 2027 revenue of $40.1 million, up approximately 10.4% from the same quarter a year earlier.
For the three months ended September 30, 2026, revenue increased $3.8 million, primarily from Elite-label amphetamine and naltrexone product lines. Income from operations rose $1.7 million, or approximately 21%, to $9.9 million. Net income attributable to common shareholders was $17.3 million. Management will discuss results and recent business developments on November 13, 2026, at 11:30 AM EST.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointRevenue of $40.1 million increased $3.8 million, approximately 10.4%, year over year in fiscal Q2 2027.
- Moderate pointOperating income of $9.9 million increased $1.7 million, approximately 21%, year over year in fiscal Q2 2027.
- Moderate pointNet income attributable to common shareholders was $17.3 million for fiscal Q2 2027.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call Scheduled for Friday, November 13, 2026 at 11:30 AM EST
Northvale, New Jersey--(Newsfile Corp. - November 12, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the Second quarter of fiscal year 2027 ended September 30, 2026 ("Second Quarter").
Consolidated revenues for the three-month period ending September 30, 2026, were
Conference Call Information
Elite's management will host a conference call to discuss the Second Quarter of Fiscal Year 2027 financial results and provide an update on recent business developments. Stockholder questions should be submitted to the company in advance of the call.
| Date: | November 13, 2026 |
| Time: | 11:30 AM EST |
| Dial-in numbers: | 1-800-346-7359 (domestic) 1-973-528-0008 (international) |
| Conference number: | 98840 |
| Questions: | dianne@elitepharma.com Financial questions by 7:00 PM EST on Thursday, November 12, 2026 |
| Audio Replay: | https://elite.irpass.com/events_presentations |
The financial statements can be viewed for Elite's Second Quarter of Fiscal Year 2027 on Form 10-Q here.
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. Elite specializes in developing, manufacturing, and distributing oral, controlled-release drug products. Elite owns multiple generic products, which it distributes nationwide under the Elite Laboratories, Inc. label. Elite operates a cGMP and DEA-registered research, development, and manufacturing facility in Northvale, NJ. For more information, visit www.elitepharma.com.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA, and the actions the FDA may require of Elite to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
www.elitepharma.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/323778
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Elite Pharmaceuticals' fiscal Q2 2027 financial results?
Elite reported $40.1 million in revenue, $9.9 million in operating income and $17.3 million in net income attributable to common shareholders for the quarter ended September 30, 2026. Revenue rose approximately 10.4% and operating income increased approximately 21% from the same period of the prior fiscal year.